The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.
本发明涉及使用式(I)的氧化
吲哚肼衍
生物治疗和/或预防由
胰岛素抵抗或高血糖介导的代谢障碍,包括1型和/或2型糖尿病、不足的
葡萄糖耐受性、
胰岛素抵抗、高脂血症、高三酰
甘油血症、高
胆固醇血症、肥胖和多囊卵巢综合症(
PCOS)。特别地,本发明涉及使用式(I)的氧化
吲哚肼衍
生物调节,特别是抑制
PTP的活性,尤其是
PTP1B、TC-
PTP、SHP和GLEPP-1的活性。本发明还涉及新的氧化
吲哚肼衍
生物及其制备方法。